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Abstract
Background: The purpose of this research was to assess agreement between four rating systems of cosmetic
outcome measured in a subset of patients with early breast cancer participating in the randomised TARGIT-A trial.
TARGIT-A compared risk-adapted single-dose intra-operative radiotherapy (TARGIT-IORT) to whole breast external
beam radiotherapy (EBRT).
Methods: Patients, their Radiation Oncologist and Research Nurse completed a subjective cosmetic assessment
questionnaire before radiotherapy and annually thereafter for five years. Objective data previously calculated by the
validated BCCT.core software which utilizes digital photographs to score symmetry, colour and scar was also used.
Agreement was assessed by the Kappa statistic and longitudinal changes were assessed by generalized estimating
equations.
Results: Overall, an Excellent-Good (EG) cosmetic result was scored more often than a Fair-Poor (FP) result for both
treatment groups across all time points, with patients who received TARGIT-IORT scoring EG more often than those
who received EBRT however this was statistically significant at Year 5 only. There was modest agreement between
the four rating systems with the highest Kappa score being moderate agreement which was between nurse and
doctor scores at Year 1 with Kappa = 0.46 (p < 0.001), 95% CI (0.24, 0.68).
Conclusion: Despite similar overall findings between treatment groups and rating systems, the inter-rater
agreement was only modest. This suggests that the four rating systems utilized may not necessarily be used
interchangeably and it is arguable that for an outcome such as cosmetic appearance, the patient’s point of view is
the most important.
Trial Registration: TARGIT-A ISRCTN34086741, Registered 21 July 2004, retrospectively registered.
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Background
Standard adjuvant treatment for women undergoing
breast conserving surgery (BCS) is whole breast external
beam radiotherapy (EBRT) delivered in 15–35 daily frac-
tions over a period of 3–7 weeks [1–6]. Several countries
have already adopted the use of Targeted Intra-
Operative Radiotherapy utilising the Intrabeam device
(TARGIT-IORT) as a form of partial breast irradiation
for suitable women, which allows the delivery of radi-
ation directly to the tissues at the site of the primary
tumour in a single session at the time of wide local
excision (WLE) or shortly afterwards. When compared
to EBRT in the TARGIT-A Trial, TARGIT-IORT was
found to be non-inferior in terms of local recurrence
with no difference in breast-cancer survival and a small
but significant improvement in non-breast-cancer sur-
vival favoring TARGIT-IORT. Unlike TARGIT-IORT de-
livered prepathology (during WLE), non-inferiority
could not be established for postpathology TARGIT-
IORT (separate to WLE), but the difference in local re-
currence was not statistically significant [7]. Within a
sub-group of the TARGIT-A trial (n = 342), cosmetic
outcome based on objective measurements was found to
be better with TARGIT IORT, particularly in the first
year after surgery [8]. Previous analysis of the present
dataset has shown similar cosmetic outcomes when
comparing TARGIT-IORT to EBRT, but better breast-
related quality of life, both as scored by patients [9].
Over time, a variety of methods to measure cosmetic
outcome have been explored due to the importance of
such secondary outcomes when assessing the acceptabil-
ity of new treatments with similar efficacy to standard
care. In 1979 Harris described a subjective assessment
utilising a four point scale comparing the treated breast
to the untreated breast. Objective measurements asses-
sing breast retraction (BRA) were described by Pezner in
1985; then further developed by Christie in 2005 with
the use of photographic assessment; then in 2007 by Fit-
zal with the Breast Analysing Tool (BAT) and by Car-
doso with the development and validation of the
BCCT.core software (Breast Cancer Conservative Treat-
ment.Cosmetic results) [10–17]. Limited reproducibility
of subjective results led to the investigation of objective
measurements, however it has been argued that patient-
assessed cosmetic outcome is the most important as it is
the woman who must live with her cosmetic outcome,
despite patients tending to score themselves more posi-
tively than their health care providers [11, 13, 18–20].
In the absence of a gold standard approach for asses-
sing cosmesis, four existing and reasonably practical
methods were utilised to compare cosmetic outcome be-
tween TARGIT-IORT and EBRT; a) subjective patient
self-assessment, b) live subjective assessment by a nurse
and c) a doctor (Radiation Oncologist), and d) digital
photographic assessment to provide an objective meas-
ure of breast retraction, colour and scar; scoring for each
assessment was based on the Harris scale [10]. This
current report expands on previously reported subjective
(patient self-assessment) [9] and objective (BCCT.core)
outcomes [8] by focusing on agreement on cosmetic
outcome between the different rating systems.
Methods
Patients and Treatment
As previously reported, 3451 patients from 33 centres in
11 countries participated in the TARGIT-A trial between
2000 and 2012 [7, 9]. Patients with early breast cancer
suitable for breast conserving surgery were randomized
to receive either a single dose of TARGIT-IORT (50 kV
X-rays with INTRABEAM(™) Carl Zeiss, Oberkochen
Germany) or conventional 3–7 weeks’ EBRT. TARGIT-
IORT patients with unfavourable pathology also received
EBRT in ~ 15% of cases however these were excluded
from this analysis. TARGIT-IORT dose to 1 cm was
5-6Gy (16-33Gy at applicator surface) and EBRT was
conventional 3-dimensional conformal radiotherapy (45–
50.4Gy in 15–28 fractions) [21].
This cosmesis sub-study includes 126 patients from 3
hospitals in Western Australia randomized predomin-
antly in the postpathology setting. Relevant ethics ap-
provals were obtained and all participants provided
written informed consent.
Eligibility for Australian patients randomized post-
pathology was stricter than the main trial; unifocal inva-
sive ductal < 2 cm tumours, node negative, hormone
receptor positive, limited DCIS and no lymphovascular
invasion. Fourteen EBRT and 4 IORT patients in this
analysis were randomised before their WLE (prepathol-
ogy stratification) where these stricter criteria did not
apply hence some deviations are shown in Table 1.
Instruments and evaluations
Cosmesis Harris Scale
Patients completed a self-reported cosmetic assessment at
baseline (before radiotherapy) and annually thereafter for
five years as previously reported [9]. At the same time
points, a Radiation Oncologist and a Research Nurse inde-
pendently completed the same cosmetic assessment for
each patient, blinded to other rater scores. Doctor and
nurse raters were also involved in patient care and were
not blinded to treatment allocation. At the same time-
points, digital photographs were taken of the unclothed
torso from neck to navel, frontal view, with the patient
standing, a method used by others [12, 22]. All baseline
measurements were taken before radiotherapy, the major-
ity being after WLE, except 3% in the TARGIT-IORT
group and 18% in the EBRT group that were taken before
WLE (where patients were randomised before their WLE
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(prepathology) earlier in the study - prior to postpathology
becoming the more common approach at the Australian
study centres).
All cosmetic assessments used the Global Harris Scor-
ing System (also known as the Harvard Scale) of Excellent,
Good, Fair or Poor (Additional file 1: Table S1) [10, 18, 23,
24]. Responses were dichotomized into Excellent-Good
(EG) or Fair-Poor (FP) categories in order to facilitate
comparison with other published studies of cosmesis. The
digital photographs were analyzed separately [8] utilizing
the validated objective BCCT.core software [14–16, 25].
Scores are referred to in the subsequent text as doctor
(Radiation Oncologist), nurse, patient and BCCT.core.
Analysis and Interpretation
Statistical significance was set at the level of p < 0.01 to
account for multiple comparisons [26, 27].
IBM-SPSS-V22 (SPSS Inc.,Chicago, IL) was used for:
non-parametric analysis (Mann-Whitney U-Tests and
Chi2 tests) of raw unadjusted data, two sample t-tests for
change between baseline and Year-5 scores, and inter-
rater reliability analysis using the Kappa statistic to de-
termine consistency among raters. Kappa scores were
interpreted based on levels of agreement described by
Landis and Koch; < 0 Poor, 0.0–0.20 Slight, 0.21–0.40
Table 1 Baseline patient characteristics by treatment
Patient, treatment and tumour
characteristics
TARGIT-IORT EBRT
Number of patients (% of total) 60 (48%) 66 (52%)
Age (mean years +/− SD)
Range
63 (+/− 8.2)
50–83
62 (+/− 7.4)
50–80
Randomised prepathology (before WLE)
Randomised postpathology (after WLE)
4 (7%)
56 (93%)
14 (21%)
52 (79%)
Baseline assessments prior to any
surgery N (% of treatment group)
2 (3%) 12 (18%)
Baseline BMI (mean score kg/m2
+/− SD)
Baseline BMI Groupa (% pf treatment
group)
29 (+/− 5.5) 30 (+/− 5.9)
1 – Underweight (< 18.5) 0% 0%
2 – Normal (18.5–24.99) 30% 16%
3 – Overweight (25–29.99) 30% 50%
4 – Obese (30+) 40% 34%
Tumour Size (mm mean ± SD)
Tumour Size Group, % of treatment
group
10 (+/− 4.2) 11 (+/− 5.0)
< 11(mm) 62% 52%
11–20 (mm) 38% 46%
> 21(mm) b – 1.5%
Tumour Grade, n (% of treatment group)
1 37 (62%) 38 (57%)
2 23 (38%) 27 (41%)
3b 0 1 (1.5%)
Tumour Type, n (% of treatment group)
IDC
Mixed IDC/ILCb
59 (98%)
1 (1.7%)
64 (97%)
2 (3%)
Lesions, n (% of treatment group)
1 60 (100%) 65 (98%)
2b 0 1 (1.5%)
Extensive DCIS (> 25% of tumour
+ inside and out of tumour)b n (%
of treatment group)
0 4 (6.3%)
Hormone receptor status, n (% of
treatment group)
ER + ve 60 (100%) 64 (97%)
PR + ve 44 (73%) 52 (79%)
ER and PR –veb 0 2 (3%)
Positive Nodesb, n (% of treatment
group)
0 1 (1.5%) (1
node)
Largest Specimen Length (mean
-mm +/− SD)
Range
89 (+/− 37.2)
25–205
89 (+/− 38.4)
40–267
Extent of Axillary Surgery, n (% of treatment group)
Nil 3 (5%) 2 (3%)
SLNBx 49 (82%) 55 (83%)
Clearance 8 (13%) 9 (14%)
Table 1 Baseline patient characteristics by treatment
(Continued)
Patient, treatment and tumour
characteristics
TARGIT-IORT EBRT
Further Surgery Required, n (% of treatment group)
SLNBx 2 (3.3%) 2 (3%)
Margins 2 (3.3%) 7 (11%)
Revision of Scar 2 (3.3%) 0
Radiotherapy Dose Range (Gy) 16-33c 45–50.4
Fractions (range) 1 25 (25–28)
Boost Given (20Gy in 10 fractions),
n (% of treatment group)
N/A 11 (17%)
Supraclavicular Treatment, n (% of
treatment group)
N/A 1 (1.5%)
Chemotherapy givenb (n, % of
treatment
group)
0 1 (1.5%)
Baseline Cosmesis Scores (% Excellent-Good), mean (± SD)
Patient Harris 85 (+/− 0.36) 82 (+/− 0.39)
Nurse Harris 93 (+/− 0.25) 92 (+/− 0.27)
Doctor Harris† 87 (+/− 0.35) 100 (+/− 0.0)
BCCT.Core 83 (+/− 0.38) 90 (0.31)
Abbreviations: WLE: Wide Local Excision; BMI: body mass index; DCIS: ductal
carcinoma in situ; EBRT = external beam radiation therapy; ER: estrogen
receptor; IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; PR:
progesterone receptor; SD: standard deviation; SLNBx: sentinel lymph node
biopsy; TARGIT-IORT: targeted intraoperative radiation therapy
aSee reference 28; b Factors relevant only to the prepathology stratification;
cDose to surface of applicator; † Significantly different (p = 0.003)
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Fair, 0.41–0.60 Moderate, 0.61–0.80 Substantial, 0.81–
1.00 Almost perfect [28]. Generalized estimating equa-
tions (GEE) with a variable covariance structure were
used for the longitudinal dichotomized cosmesis end-
point scored by doctors and nurses using SAS-V9.3
(SAS Institute, Cary, NC).
Results
Of the 385 Western Australian patients randomized into
the TARGIT-A trial, the first 152 consecutive patients
were invited to participate in this sub-study (further re-
cruitment ceased due to resource constraints). Six de-
clined participation; a further 20 were excluded due to
confounders which would render cosmesis data uninter-
pretable, including (1) received both TARGIT-IORT and
EBRT (n = 9); (2) received TARGIT-IORT during WLE
(n = 1); (3) no radiotherapy given (n = 2); or (4) history
of contralateral disease (n = 8). This left 126 evaluable
participants, of whom 60 had TARGIT-IORT and 66 had
EBRT (Fig. 1).
Participants and Compliance
Initial compliance was very good and nearly identical
across both treatment groups for all four rating systems
but decreased over time. Availability of BCCT.core data
at Years 3 and 4 fell below 50% and there was no data
available at Year-5 (Additional file 1: Table S2).
Baseline patient characteristics were not different be-
tween treatment groups (Table 1).
Cosmesis
At baseline, doctor scores for cosmesis were significantly
better than results scored by patients in the EBRT group
than the TARGIT-IORT group (100% vs. 87% Fisher’s
Exact p = 0.003). Overall after treatment, a greater propor-
tion of TARGIT-IORT patients scored an EG result com-
pared to EBRT patients. Longitudinal multivariate analysis
of cosmesis scores rated by doctors and nurses revealed no
significant differences between patients treated with
TARGIT-IORT and patients treated with EBRT (Additional
file 1: Table S3). Un-dichotomized Harris Scale data are avail-
able in Additional file 1: Table S4.
Fisher’s exact Chi-squared univariate analysis for each
rating system revealed three significantly different time
points; patient Year-5 scores were the most divergent,
with 90% and 68.4% scoring an EG response for the
TARGIT-IORT and EBRT groups respectively (p = 0.042)
[9], followed by the Year-2 Nurse scores (88.9% vs.
69.1%, p = 0.018) and then baseline doctor scores of
86.5% and 100% respectively (p = 0.003). Logistic regres-
sion with and without potential confounding variables
(age, BMI, tumour size, tumour grade) did not alter
these findings.
The proportion of EBRT patients achieving an EG out-
come failed to return to the baseline proportion in the 4–
5 years of follow-up across all rating systems however this
was not statistically significant for any of the rating sys-
tems (Fig. 2). Patients who received EBRT also had a non-
significant poorer outcome at Year-5 when compared to
baseline for all subjective rating systems (p = 0.15 patients;
p = 0.11 doctors; p = 0.05, nurses).
To test whether additional factors, including age, time
since treatment, body mass index (BMI) and specimen
size may have an impact on cosmetic outcome scores,
Generalized Estimating Equation Models were con-
structed including these factors. Time since treatment and
BMI were found to be related to cosmetic outcome at
some, but not all time points (Additional file 1: Table S3)
[29]. In the model examining nurse scores, cosmesis
outcomes in Years 1, 2 and 3 were scored signifi-
cantly worse than baseline (p = 0.004) for both treat-
ment groups. Similarly, the model examining doctor
scores found Year 1, 3 and 5 cosmetic outcome to be
worse than baseline for both treatments (p = 0.018).
Also in the doctor model, it was found that as patient
BMI increased, the likelihood of scoring an EG result
decreased (Estimate − 0.8, p = 0.009).
Review of agreement between cosmesis rating systems
Inter-rater reliability analysis revealed only 5 statistically
significant Kappa scores out of the 36 observed time
point pairings (Table 2). Four of these showed only fair
agreement between raters. Only one time point scored
moderate agreement which was between nurse and
Fig. 1 CONSORT diagram
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doctor scores at Year 1 with Kappa = 0.46 (p < 0.001),
95% CI (0.24, 0.68).
One can see that most of the variation in responses
was in the EBRT arm. BCCT.core correlated well with
patient scores in the TARGIT-IORT group but not in
the EBRT group (Fig. 3).
Figure 3 illustrates that each rating system followed a
similar trend, with overall cosmesis scores showing 25%
variation between raters within each of the 5 time
points. Rater disagreement was seen such that doctors
gave the most positive scores, followed by nurses, then
patients and then BCCT.core. The significantly different
time points (p < 0.01) between raters were Year 1 (doc-
tors and BCCT.core both gave worse scores than nurses;
doctors and nurses scored cosmesis better than patients)
and Year 2 (BCCT.core gave worse scores than nurses)
(Table 3).
In terms of percentage agreement, nurse and doctor
scores appeared to be the most closely related with an
overall agreement of 80.8%; range 73.5% (Year 2) to
88.3% (baseline) (Table 2). The rating system that ap-
peared most similar to the patient scores overall was the
doctor scores, with an overall agreement of 78.6%; range
73.2% at Year 3 to 80.8% at baseline).
Sensitivity Analysis
The effect of missing data on the patient scores at Year-
5 was tested by substituting the previous years’ result.
For the EBRT group, this increased the proportion of an
EG score from 68.4% to 69% and for the TARGIT-IORT
group it decreased the proportion from 90% to 88%.
Discussion of results
Since its first use in 1998, intraoperative radiotherapy
has been tested in randomised clinical trials and offered
as adjuvant breast radiotherapy for over 20,000 women.
Given the fact that breast cancer local recurrence out-
comes are no different with TARGIT-IORT compared
with EBRT, the obvious difference in patient experience
(a single treatment instead of several weeks of daily
treatments in the hospital) is of great importance.
Cosmetic outcome post various forms of intra-operative
radiotherapy has been previously reported [8, 9, 30–34]
however no study has compared four different rating sys-
tems, even with other approaches of breast conserving
therapy. The earliest cosmetic assessment of TARGIT-
IORT utilised a satisfaction index by asking patients to
give a score for what she expected (E) and another for
what she observed (O). It was found that for appearance,
Fig. 2 Cosmesis Outcomes (% Excellent-Good) by Rater. 95% Confidence Intervals displayed are the upper limits for the TARGIT-IORT group and
the lower limits for the EBRT group
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there was a trend for better scores for TARGIT IORT
boost compared with EBRT and no difference between the
two treatments was found for the satisfaction indices for
texture [35, 36]. The current TARGIT-A sub-study
assessed the agreement in cosmetic outcome between one
objective and three subjective rating systems, by investi-
gating the proportion of patients scoring an Excellent-
Good (EG) outcome in each treatment group. Overall, the
majority of patients in both treatment groups scored an
EG cosmetic result across all scoring systems, however
32% (12/38) of EBRT patients assessed at Year-5 self-
reported a Fair-Poor result. This compares poorly to the
90% of TARGIT-IORT patients (27/30 patients) self-
reporting an EG result at this time-point, but nearly fits
within the previously reported expectation that overall,
70–80% of EBRT patients will have an EG result [37]. Of
those not providing a score at Year-5 due to having with-
drawn (n = 3) or non-compliance (n = 11), 5 out of 7 from
the EBRT group had a previous EG score and 3 out of 4
from the TARGIT-IORT group had a previous EG score,
suggesting that had they provided a 5 year score which
maintained their previous score, the proportions may have
been 69% and 88% respectively. This suggests study attri-
tion did not cause the large difference at this time point.
Further discussion about the patient-reported findings has
been detailed elsewhere [9].
It is well known that EBRT can have a negative impact
on long term cosmetic outcome. This was confirmed in
this study, with the EBRT group failing to reach baseline
proportions of EG scores across all follow-up time
points and all rating systems. Although follow-up scores
when compared to baseline scores were not statistically
significantly different between the TARGIT-IORT and
EBRT groups in the subjective measurements, TARGIT-
IORT patients did reach baseline proportions of EG
scores in all rating systems, from Year-3 or 4 onwards.
This suggests IORT patients do experience an initial de-
cline in cosmesis but this improves beyond the second
year of follow-up. Baseline assessments were taken prior
to surgery in 1 patient in the EBRT arm (2%) and 12
patients (18%) in the TARGIT-IORT arm, which may
introduce some bias in the interpretation of these
results. Previously reported BCCT.core data showed pa-
tients receiving TARGIT-IORT were significantly more
likely to have an EG result at Year 1 and Year 2, com-
pared to patients who received EBRT [8]. The only time
point to have moderate agreement between two raters
was Year-1, between nurses and doctors, when cosmesis
scores were poorer than at other time points. This sug-
gests that for both treatment groups, cosmetic outcome
assessed by all raters reached a nadir at Year-1.
Overall, a higher proportion of patients in the present
study had an EG result compared to other different mo-
dalities of intraoperative radiotherapy. The Montpellier
study (IORT delivered via a linear accelerator) reported
‘Excellent to Good’ cosmetic scores at 6 months and a
Mammosite study (utilizing a balloon applicator) found
84% and 78% Excellent to Good scores at Years 1 and 2
respectively [30, 31]. Cosmetic assessments for these two
studies were made by a clinician from physical assess-
ments and photographic review and were not patient
reported. Cosmetic outcome data from the ELIOT study
Fig. 3 Cosmesis Outcomes (% Excellent-Good) by Treatment
Table 3 Inter-rater Reliability – Significant Kappa Scores
Time point Rater Comparison (% EG) Kappa p-value
1 Year Patient (76) vs. Doctor^ (82) 0.312** 0.006 ##
1 Year Patient (76) vs. Nurse (78)^ 0.366** 0.001 ##
1 Year Patient (76)^ vs. BCCT (68) 0.222** 0.034 #
1 Year Nurse (78) vs. Doctor (82)^ 0.461*** < 0.001 ##
1 Year Nurse (78)^ vs. BCCT (68) 0.345** < 0.001 ##
2 Year Patient (80) vs. Doctor (87)^ 0.258** 0.018 #
2 Year Doctor (87)^ vs. BCCT (77) 0.211** 0.048 #
2 Year Nurse (79)^ vs. BCCT (77) 0.314** 0.005 ##
3 Year Nurse (78) vs. BCCT (81)^ 0.348** 0.020 #
5 Year Patient (79) vs. Doctor (84)^ 0.258** 0.027 #
**Fair agreement ***Moderate agreement ## p < 0.01 # < 0.05 ^scored higher
proportion as EG
Corica et al. Radiation Oncology  (2018) 13:68 Page 7 of 10
(using 21Gy electron intra-operative radiotherapy) was re-
ported as ‘good’ in the majority of cases, scored by both
patients and clinicians [32]. A South African study deliver-
ing Iridium192 via after-loader found that 74% of patients
reported an EG score after 7 years of follow-up [33].
Historically, patients have been known to evaluate cos-
metic outcome more favourably than their clinicians, pos-
sibly due to a range of psychological factors; not wanting to
displease their clinicians (or their teams) is a common sug-
gestion. It may also be that factors other than aesthetics in-
fluence a patient’s evaluation of cosmetic outcomes; it may
be related to quality of life, expectations or the difference in
interpretation of what the Harris Scale means between dif-
ferent raters [20, 38, 39]. In this study, we found that pa-
tients’ self-assessments were similar to the objective
assessment of the BCCT.core software, but only in those
who received TARGIT-IORT, perhaps influenced by the
better breast related quality of life with TARGIT-IORT [9].
Previous studies utilizing BCCT.core [17, 38, 39] have
found that patients receiving EBRT score better than BCCT
software. In this study, doctors were most likely to report
an Excellent or Good outcome, followed by nurses. These
results confirm previous research that subjective Harris
Scale scores reported by the patient, her doctor and a nurse
should not be used interchangeably [12, 13, 17].
Guidelines produced by the EORTC in 2006 stated
that since there was no ‘gold standard’, at least 3 mea-
sures should be used to assess cosmetic outcome: a sub-
jective panel of 5 members using the Harris Scale; some
form of objective measurement system; and some form
of skin damage grading, however this may not always be
practical [17, 40].
Some authors have stated that, as patients have to live
with the outcome of treatment, the patient self-
assessments are the most important; although some con-
test that due to the low reproducibility of such results
and the high dependence on psycho-social factors, they
should be measured in conjunction with an objective
measurement system (13, 17, 19, 34). An approach used
in the past has been blinded review by two or more radi-
ation oncologists, however the BCCT.core system was
used instead of blinded review in the present study. Even
though BCCT software is an objective assessment, we
posit that the most practical and perhaps most relevant
measurements are those carried out by the patient her-
self. This is particularly true when it is used within the
context of a randomised trial, as all other factors would
be equally balanced between the two arms and any effect
would be attributable to the randomised allocation and
should reflect the real-world scenario. It would be ideal
to use all four methods in every study, or a combination
of at least two, but as the other methods are more re-
source intensive and if they don’t correlate with the pa-
tient perception, they are arguably less relevant.
Limitations and Strengths
During the design of the present study there was no
standardised approach for measuring cosmesis post
breast conserving surgery in randomised controlled trials
[40]. At the time, a combination of several measures was
considered better than one, hence four available and
practical measures were undertaken (patient, doctor,
nurse, and digital photographs in accordance with the
Christie protocol [12, 22]). It was not until later that the
BCCT.core software became available and subsequently
applied to the photographs as a more contemporary
computerised assessment technology than the originally
planned Christie approach [8]. This study had excellent
compliance rates for patient, nurse and doctor scores;
however, digital photographs were not available for many
patients towards the end of the study, which resulted in
missing data for the objective cosmesis measurements.
The impracticalities of annual photography contributed
to the restriction of this sub-study to the first 152 pa-
tients registered in Western Australia [17] and reduced
compliance in the later years, with the large geographical
dispersion of patients in Western Australia potentially
influencing return to the study centre. Image quality was
also an issue, with some photographs not meeting the
requirements for assessment by BCCT.core. The propor-
tion of available BCCT.core data at Year 3 and Year 4
was only 44% and 27% respectively, hence the later
BCCT results should be considered with caution. With
current and future technology, and the awareness of the
BCCT.core software, image quality should not be a
problem for future prospective trials.
Doctor and nurse scores were not formally blinded to
treatment received which may be a potential source of
bias. Despite using a standard protocol, the doctor and
nurse scores may also attract intra-rater bias as different
doctors and nurses may have completed the cosmesis
Harris scores. It was impractical to have the same asses-
sors or photographers at each visit for the long duration
of the study; however it was always the same patient
assessing herself each time. This consistency is yet an-
other argument to rely more on the patient’s own assess-
ment than any other.
Another limitation is that there may be cultural differ-
ences in attitude to cosmetic outcome that may reduce
the generalisability of the inter-rater results to different
populations.
Conclusion
As found in previous studies, a numerically higher propor-
tion of patients treated with TARGIT-IORT had an
Excellent-Good outcome compared with those who re-
ceived EBRT. In this study, we found that there was little
agreement between the four cosmetic rating systems used;
in particular, patients’ score did not always correlate with
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the scores by doctors, nurses or the BCCT.core software.
While on one hand, the objective assessment of cosmetic
outcome used along with subjective assessments by staff
and patients may be the ideal way to assess cosmesis, it
can be argued that patient opinion of cosmetic outcome is
the most important and may be the only outcome mea-
sured, particularly when resources are limited. In a rando-
mised trial, the patient’s own assessment would give the
most realistic measure of the difference in the cosmetic
impacts of compared treatments.
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